Metza Kristen 4
4 · GILEAD SCIENCES INC · Filed Nov 5, 2012
Insider Transaction Report
Form 4
Metza Kristen
SVP, Human Resources
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
2012-11-01−14,000→ 19,600 totalExercise: $38.17Exp: 2021-01-20→ Common Stock (14,000 underlying) - Exercise/Conversion
Common Stock
2012-11-01$43.15/sh+2,000$86,300→ 55,305 total - Sale
Common Stock
2012-11-01$68.18/sh−2,800$190,898→ 25,305 total - Exercise/Conversion
Common Stock
2012-11-01$47.51/sh+14,000$665,140→ 53,305 total - Sale
Common Stock
2012-11-01$67.68/sh−27,200$1,840,768→ 28,105 total - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
2012-11-01−2,000→ 3,500 totalExercise: $43.15Exp: 2018-01-30→ Common Stock (2,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
2012-11-01−14,000→ 12,600 totalExercise: $47.51Exp: 2020-01-28→ Common Stock (14,000 underlying) - Exercise/Conversion
Common Stock
2012-11-01$38.17/sh+14,000$534,380→ 39,305 total
Footnotes (5)
- [F1]The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Metza on February 22, 2011.
- [F2]The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- [F3]The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- [F4]Sale prices reported for the transactions reported here range from $67.12 to $68.12. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- [F5]Sale prices reported for the transactions reported here range from $68.13 to $68.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.